Search | Clinical Trials Finder

Conditions: Primary Brain Tumor, Brain Tumor, Recurrent
Interventions: Fluoxetine, Temozolomide; Drug
Lead sponsor: Duke University; Other
Eligibility: 24 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: San Diego, California • Stanford, California • New York, New York + 1 more

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo, Intervention B Vilazodone Hydrochloride (HCl), Intervention B Placebo, Intervention C Daridorexant, Intervention C Placebo, Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Major Depression, End Stage Renal Disease
Interventions: Fluoxetine, Bupropion; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 30 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: OPC-34712, Escitalopram, Fluoxetine, Paroxetine CR, Sertraline, Duloxetine, Venlafaxine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,944 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 93
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 90 more

Conditions: Premenstrual Syndrome
Interventions: Fluoxetine, Calcium, Placebo; Drug
Lead sponsor: Donaghue Medical Research Foundation; Other
Eligibility: 18 Years to 48 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder
Interventions: Venlafaxine ERT, Fluoxetine; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Fluoxetine, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 51
States / cities: Little Rock, Arkansas • Beverly Hills, California • Corona, California + 45 more

Conditions: Borderline Personality Disorder
Interventions: Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Low Back Pain, Pain, Pain, Intractable
Interventions: Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics; Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention A Fluoxetine Hydrochloride (HCl), Intervention A Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Adolescent Depression
Interventions: Fluoxetine, Increased Dose of Interpersonal Psychotherapy, Continue to Receive Initial Dose of Interpersonal Psychotherapy; Drug · Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Autistic Disorder
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 30 Months to 58 Months
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: New York, New York • Chapel Hill, North Carolina

Conditions: Fibromyalgia
Interventions: Amitriptyline, Amitriptyline plus Fluoxitine; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 7
States / cities: Brockton, Massachusetts • Fall River, Massachusetts • Framingham, Massachusetts + 4 more

Conditions: Depression
Interventions: Fluoxetine 20 MG, Duloxetine 30 MG, Observation; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Sleep Initiation and Maintenance Disorders, Depression
Interventions: Eszopiclone, Fluoxetine, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Borderline Personality Disorder, Suicide
Interventions: Fluoxetine, DBT, Citalopram; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major, Cannabis Abuse
Interventions: Fluoxetine, Placebo; Drug · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 25 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19, Cytokine Storm
Interventions: Fluoxetine; Drug
Lead sponsor: University of Toledo Health Science Campus; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Major Depressive Disorder
Interventions: mixed salts amphetamine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depression
Interventions: fluoxetine, placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 627 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2003
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Cognitive Dysfunction
Interventions: Fluoxetine, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: Duarte, California • Los Angeles, California

Conditions: Depression
Interventions: Sleep scheduling, Fluoxetine; Behavioral · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Department of Defense PTSD Adaptive Platform Trial - Master Protocol

Bupropion for Depression in ESRD Patients on Hemodialysis

Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)

Comparison of Fluoxetine, Calcium and Placebo for the Treatment of Moderate to Severe Premenstrual Syndrome (PMS)

Brain Imaging Techniques That Predict Antidepressant Responsiveness

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

Department of Defense PTSD Adaptive Platform Trial - Intervention A - Fluoxetine

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

An Adaptive Treatment Strategy for Adolescent Depression

Early Intervention With Fluoxetine in Autism

Combining N-of-1 Trials to Assess Fibromyalgia Treatments

Identifying and Treating Depression in the Orthopaedic Trauma Population

Improving Sleep and Psychological Functioning in People With Depression and Insomnia

Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder

Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence

Fluoxetine to Reduce Intubation and Death After COVID19 Infection

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Prozac Treatment of Major Depression: Discontinuation Study

Fluoxetine Prevention Trial

Repeated Partial Sleep Deprivation to Augment SSRI Response in Depression